Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.
We compared the changes in weight (kg) and body mass index (BMI) (kg/m(2)) in 52 hospitalized adolescents between baseline and after 12 weeks of monotherapy with either (i) olanzapine (OLZ) orally disintegrating tablets (ODT) (N=16; 16.6 mg/day+/-4.4 [SD]), or (ii) OLZ standard oral tablets (SOT) (N=10; 18.0 mg/day+/-4.2), or (iii) risperidone (N=26; 2.8 mg/day+/-1.2). Significantly greater increases in mean weight and BMI were observed in the patients treated with OLZ SOT (8.9+/-5.1 [SD] kg; 1.9+/-0.6 kg/m(2), respectively) than in those with ODT (3.0+/-2.1 kg; 1.1+/-0.8 kg/m(2)). Similarly, OLZ ODT treatment was associated with significantly greater increases in weight and BMI than risperidone (1.0+/-1.8 kg; 0.4+/-0.7 kg/m(2)). These findings suggest that adolescents gain less weight with OLZ ODT than OLZ SOT, possibly because the former formulation shortens the time of interaction with digestive serotonin receptors mediating satiety.
Crocq
Marc-Antoine
MA
Centre Hospitalier, Service de Psychiatrie de l'Adolescent, BP29, 68250 Rouffach, France. ma.crocq@ch-rouffach.fr
Guillon
Marie-Sa
MS
Bailey
Paul Ernest
PE
Provost
Dominique
D
D000284:Administration, Oral; D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D004333:Drug Administration Routes; D005260:Female; D006801:Humans; D008297:Male; D000077152:Olanzapine; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000534:rehabilitation*; D013607:Tablets; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D013607:Tablets; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine